VivoSeq
Infectious Disease

Onchocerciasis

10

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Onchocerciasis is an early-stage landscape with 10 programs across 5 companies. The most active players are GSK, Medicines Development for Global Health, Sanofi. 4 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 3M

Medicines Development for Global Health

1 program

ApprovedSanofi logo

Sanofi

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedC

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

17

clinical trials

Completed12 · 71%
Active, not recruiting3 · 18%
Recruiting2 · 12%

Clinical Trials

Trial Activity

17 trials

Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
Recruiting·KKirby Institute·Phase 4·NCT07145736·52,000 enrolled
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Recruiting·BBioaster·N/A·NCT06350851·400 enrolled
Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT06070116·300 enrolled
Emodepside Phase II Trial for Treatment of Onchocerciasis
Active, not recruiting·DDrugs for Neglected Diseases·Phase 2·NCT05180461·578 enrolled
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Active, not recruiting·MMedicines Development for Global Health·Phase 3·NCT03876262·323 enrolled
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
Completed·WWashington University School of Medicine·N/A·NCT02899936·23,789 enrolled
IVM Alone vs ALB + IVM Against Onchocerciasis
Completed·UUniversity Hospitals Cleveland Medical Center·Phase 3·NCT03238131·272 enrolled
Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
Completed·UUniversiteit Antwerpen·N/A·NCT05749653·6,500 enrolled
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Completed·WWashington University School of Medicine·N/A·NCT01905436·21,862 enrolled
Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan
Completed·UUniversiteit Antwerpen·N/A·NCT05750043·17,000 enrolled
Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy
Completed·UUniversiteit Antwerpen·Phase 4·NCT03852303·197 enrolled
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
Completed·—·Phase 4·NCT03052998·91 enrolled
Safety and Efficacy of IDA for Onchocerciasis
Completed·WWashington University School of Medicine·Phase 2·NCT04188301·154 enrolled
Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
Completed·UUniversity Hospitals Cleveland Medical Center·Phase 3·NCT02078024·375 enrolled
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Completed·WWashington University School of Medicine·N/A·NCT01905423·17,108 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)